文献速递心脑血管急症消化、代谢与肾脏急症

BNT162b2 mRNA新冠疫苗在全国性大规模接种中的安全性

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
PubMed 文献 · N Engl J Med · 2021-08-25
一句话结论全国性匹配队列显示BNT162b2疫苗未增加多数不良事件风险,但心肌炎风险轻度升高(每10万人1-5例),而SARS-CoV-2感染后心肌炎及其他严重不良事件风险显著更高。

本研究利用以色列最大卫生组织数据,对无既往相关诊断者按社会人口学和临床变量进行个体匹配,比较接种BNT162b2疫苗者与未接种者42天内不良事件风险比和风险差。接种组与对照组各约884,828人。疫苗接种与心肌炎(RR 3.24,RD 2.7/10万)、淋巴结病(RR 2.43,RD 78.4/10万)、阑尾炎(RR 1.40,RD 5.0/10万)和带状疱疹感染(RR 1.43,RD 15.8/10万)风险升高相关。SARS-CoV-2感染则与心肌炎(RR 18.28,RD 11.0/10万)及心包炎、心律失常、深静脉血栓、肺栓塞、心肌梗死、颅内出血和血小板减少症等严重不良事件风险显著增加相关。临床意义在于:疫苗总体安全,心肌炎风险虽轻度升高但远低于感染后风险。

要点

  • 接种BNT162b2疫苗后42天内心肌炎风险轻度升高:RR 3.24(95%CI 1.55-12.44),风险差2.7例/10万人(95%CI 1.0-4.6)。
  • 接种疫苗后淋巴结病风险差为78.4例/10万人(95%CI 64.1-89.3),RR 2.43(95%CI 2.05-2.78)。
  • 接种疫苗后阑尾炎风险轻度升高:RR 1.40(95%CI 1.02-2.01),风险差5.0例/10万人(95%CI 0.3-9.9)。
  • 接种疫苗后带状疱疹感染风险轻度升高:RR 1.43(95%CI 1.20-1.73),风险差15.8例/10万人(95%CI 8.2-24.2)。
  • SARS-CoV-2感染后心肌炎风险显著升高:RR 18.28(95%CI 3.95-25.12),风险差11.0例/10万人(95%CI 5.6-15.8),且心包炎、心律失常、深静脉血栓、肺栓塞、心肌梗死、颅内出血和血小板减少症风险亦增加。

适用人群与场景

  • 全国性大规模接种背景下的以色列人群,接种分析中无既往相关不良事件诊断者,按社会人口学和临床变量个体匹配接种与未接种者;感染分析中SARS-CoV-2感染者与未感染者匹配。
  • 原文未提及急诊、ICU或院前等具体场景,亦未明确排除标准。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及需立刻处理或不能漏诊的具体红旗征及处理。

研究设计与关键结果

  • 研究类型:基于以色列最大卫生组织数据的全国性匹配队列研究;接种分析中接种组与对照组各平均884,828人;感染分析为SARS-CoV-2感染者与未感染者匹配。
  • 接种BNT162b2疫苗后42天内心肌炎风险升高:RR 3.24(95%CI 1.55-12.44),风险差2.7例/10万人(95%CI 1.0-4.6)。
  • 接种疫苗后淋巴结病风险升高:RR 2.43(95%CI 2.05-2.78),风险差78.4例/10万人(95%CI 64.1-89.3)。
  • 接种疫苗后阑尾炎风险升高:RR 1.40(95%CI 1.02-2.01),风险差5.0例/10万人(95%CI 0.3-9.9)。
  • 接种疫苗后带状疱疹感染风险升高:RR 1.43(95%CI 1.20-1.73),风险差15.8例/10万人(95%CI 8.2-24.2)。
  • SARS-CoV-2感染后心肌炎风险显著升高:RR 18.28(95%CI 3.95-25.12),风险差11.0例/10万人(95%CI 5.6-15.8);感染还与心包炎、心律失常、深静脉血栓、肺栓塞、心肌梗死、颅内出血和血小板减少症等严重不良事件风险增加相关。

证据类型、等级与局限

  • 证据类型:全国性匹配队列研究;原文未给出证据等级或推荐强度。
  • 局限性:原文未明确列出局限性;研究设计为观察性匹配队列,存在未测量混杂可能。

对床旁实践的改变

  • 原文未提及对急诊或ICU具体实践的改变。

指南或共识出处

  • 原文未提及指南或共识出处;研究由哈佛医学院Ivan and Francesca Berkowitz Family Living Laboratory Collaboration与Clalit Research Institute资助。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Preapproval trials showed that messenger RNA (mRNA)-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation of the safety of the BNT162b2 mRNA vaccine with respect to a broad range of potential adverse events is needed.

METHODS: We used data from the largest health care organization in Israel to evaluate the safety of the BNT162b2 mRNA vaccine. For each potential adverse event, in a population of persons with no previous diagnosis of that event, we individually matched vaccinated persons to unvaccinated persons according to sociodemographic and clinical variables. Risk ratios and risk differences at 42 days after vaccination were derived with the use of the Kaplan-Meier estimator. To place these results in context, we performed a similar analysis involving SARS-CoV-2-infected persons matched to uninfected persons. The same adverse events were studied in the vaccination and SARS-CoV-2 infection analyses.

RESULTS: In the vaccination analysis, the vaccinated and control groups each included a mean of 884,828 persons. Vaccination was most strongly associated with an elevated risk of myocarditis (risk ratio, 3.24; 95% confidence interval [CI], 1.55 to 12.44; risk difference, 2.7 events per 100,000 persons; 95% CI, 1.0 to 4.6), lymphadenopathy (risk ratio, 2.43; 95% CI, 2.05 to 2.78; risk difference, 78.4 events per 100,000 persons; 95% CI, 64.1 to 89.3), appendicitis (risk ratio, 1.40; 95% CI, 1.02 to 2.01; risk difference, 5.0 events per 100,000 persons; 95% CI, 0.3 to 9.9), and herpes zoster infection (risk ratio, 1.43; 95% CI, 1.20 to 1.73; risk difference, 15.8 events per 100,000 persons; 95% CI, 8.2 to 24.2). SARS-CoV-2 infection was associated with a substantially increased risk of myocarditis (risk ratio, 18.28; 95% CI, 3.95 to 25.12; risk difference, 11.0 events per 100,000 persons; 95% CI, 5.6 to 15.8) and of additional serious adverse events, including pericarditis, arrhythmia, deep-vein thrombosis, pulmonary embolism, myocardial infarction, intracranial hemorrhage, and thrombocytopenia.

CONCLUSIONS: In this study in a nationwide mass vaccination setting, the BNT162b2 vaccine was not associated with an elevated risk of most of the adverse events examined. The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events was substantially increased after SARS-CoV-2 infection. (Funded by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2021. PMID: 34432976. doi:10.1056/NEJMoa2110475

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。